Share Placing to raise £350,000 and TVR

GenIP Plc (AIM:GNIP), a technology consultancy providing AI-driven services to help research organisations and corporations commercialise their innovations, is pleased to announce a fundraising of £350,000 (c.US$470,000) (gross) through a placing of 5,000,000 new ordinary shares of £0.00425 each in the Company ("Placing Shares") at a price of 7p ("Issue Price") per Placing Share (the "Placing" or "Fundraising").

Key Highlights:

• £350,000 (US$470,000) before expenses raised pursuant to the Placing of 5,000,000 Placing Shares at a price of 7p per Placing Share.
• Funds raised will be utilised as follows:
• £100,000 for staffing, including account management staff to manage the increasing network of partnerships and alliances.
• £150,0000 for R&D efforts associated with new product development and platform development; and
• £100,000 for general working capital purposes, including Fundraising fees.

GenIP continues to deliver positive trading, has strengthened its relationships with academia clients and its recent alliance with Cardinal IP. The Company recently secured a contract with a university in Peru, which means that it now operates across 33% of South American nations. It has also signed a new corporate contract with a healthcare innovation client in Spain increasing its footprint in Europe and providing access to a network of 122 research groups.

Melissa Cruz, GenIP's CEO, commented:

"This Fundraise comes at a time of significant commercial momentum for GenIP. The proceeds will enable us to improve the monetization of the increasing network of partnerships and alliances and continue the programme of product development. This places the Company in a stronger position for a successful rest of FY2026."

Placing

The Company has raised £350,000 (before expenses) through the issue of 5,000,000 Placing Shares at an issue price of 7p per Placing Share, which represents a discount of approximately 38% to the closing mid-price of 11.25p as at the close of business on 30 April 2026, being the last practicable date prior to publication of this announcement. The Placing Shares represent approximately 24.4% of the Company's existing issued share capital. The Placing was undertaken by CMC Markets UK Plc ("CMC"), trading as CapX, who acted as the Company's sole placing agent in respect of the Placing.

The net proceeds of the Placing will support GenIP's growth plans, will strengthen the Company's balance sheet and provide additional working capital.

Appointment of Joint Broker

The Company is also pleased to announce that CMC has been appointed as the Company's joint corporate broker with immediate effect.

Application for Admission

Application will be made for the Placing Shares to be admitted to trading on AIM ("Admission"). It is expected that Admission will take place and that trading will commence on AIM at 8.00 a.m. on or around 8 May 2026. Once issued, the Placing Shares will rank pari passu with the Company's existing Ordinary Shares.

Total Voting Rights

Following Admission of the Placing Shares, the enlarged issued share capital of the Company will comprise 25,517,461 Ordinary Shares. The Company does not hold any Ordinary Shares in treasury. Consequently, 25,517,461 is the figure which may be used by shareholders from Admission as the denominator for the calculation by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the FCA's Disclosure and Transparency Rules.

Concert Party interest

The Concert Party (as defined in the Admission Document published on 26 September 2024), is currently interested in aggregate in 60.88% of the existing issued share capital reducing to 48.95% in the enlarged issued share capital on Admission. Accordingly, following Admission the members of the Concert Party will hold less than 50 per cent. of the voting rights in the Company but will continue to hold more than 30 per cent. of the voting rights of the Company. If a Concert Party member is in any doubt about the current position, it should consult the Company and seek their own financial advice from an appropriately authorised stockbroker, bank manager, solicitor, accountant or other independent financial adviser who, if taking advice in the United Kingdom, is duly authorised under the Financial Services and Markets Act 2000 ("FSMA").

Service Offerings

GenIP operates through two synergistic service lines:

Together, these services form a unified GenAI-enabled platform for innovation triage and commercialisation.

Vision & Strategy

Organic Expansion

Scale Invention Intelligence and Recruitment Services through targeted outreach to corporates, VCs, and research institutions.

• Service Deepening
• Strategic Acquisitions